mRNA (16) . Consistent with these immune-regulatory properties, IL-10 has been shown to downregulate neutrophil and eosinophil influx into the lungs following allergen challenge in mice (27) .
Development of airway hyperresponsiveness (AHR) in murine models of asthma is dependent on development of Th2-mediated inflammation. Specifically, IL-4, IL-5, eosinophils, and Th2 lymphocytes have all been implicated in the development of AHR (13) . IL-10 is also categorized as a Th2 cytokine (15) but downregulates allergic inflammation as well as Th1 responses. IL-10 levels in bronchoalveolar lavage (BAL) fluid (BALF) increase gradually following allergen challenge (24) and appear to be involved in the resolution of allergic inflammation (1) . Consistent with this hypothesis, instillation of recombinant murine IL-10 (rmIL-10) into the airways of BALB/c mice at the time of allergen challenge reduces IL-4 and IL-5 concentrations in BALF and subsequent recruitment of eosinophils to the airways (24, 27) . Despite the reduction of Th2 inflammatory responses, instillation of IL-10 into the airways does not reduce AHR but rather increases methacholine (MCh) responsiveness (24) .
In this study, the development of AHR following ragweed (RW) allergen challenge was compared in IL-10-deficient (IL-10-KO) and wild-type (WT) C57BL/6 mice to test the hypothesis that IL-10 reduces airway inflammation concurrent with an augmentation of AHR. The results demonstrate that, in the absence of IL-10, AHR to MCh exposure does not occur despite upregulation of Th2 inflammation. In addition, instillation of rmIL-10 at the time of RW challenge induces AHR development while reducing multiple inflammatory components by ϳ50% in IL-10-KO mice. These data support a dual role for IL-10 as an anti-inflammatory signal that independently augments AHR.
MATERIALS AND METHODS
Animals. Male C57BL/6J WT, IL-10-KO C57BL/6J, and B6.CB.17 scid [severe combined immunodeficient (SCID)] mice 6-10 wk old were purchased from Jackson Laboratories (Bar Harbor, ME) and maintained by the Department of Comparative Medicine at the Brody School of Medicine at East Carolina University (Greenville, NC). All experimental procedures were approved by the Brody School of Medicine Animal Care and Use Committee.
Allergic sensitization of C57BL/6J WT and IL-10-KO mice. Mice were sensitized by two intraperitoneal injections of RW (83 g/injection, Lot 56-129; endotoxin content Ͻ2.3 ng/mg; Greer Laboratories, Lenoir, NC) in 25 l of Imject Alum (Pierce, Rockford, IL) and 75 l of PBS. Injections were given 4 days apart. Seven days after the second intraperitoneal injection, mice were anesthetized with 90 mg/kg ketamine and 10 mg/kg xylazine and challenged by intratracheal administration of 8 g of RW in PBS.
Inflammation and airway reactivity were evaluated in separate groups of animals on day 14 (i.e., 72 h after allergen challenge). The mice were anesthetized with 90 mg/kg ketamine and 10 mg/kg xylazine and challenged by intratracheal instillation of 8 g of RW in 100 l of PBS. For protocols calling for reconstitution of IL-10 levels in IL-10 KO mice, rmIL-10 (R&D Systems, Minneapolis, MN) was administered intratracheally (it) on day 11 concomitant with allergen challenge. IL-10 was mixed with the RW challenge solution to achieve a dose of 1 ng per animal.
BALF cell counts and cytokine determinations. Animals were anesthetized with ketamine (90 mg/kg body wt) and xylazine (10 mg/kg body wt), and the lungs were lavaged with two 0.75-ml aliquots of PBS to evaluate inflammation. The BALF cells and supernatants were collected by centrifugation at 800 g for 5 min. The recovered cells were resuspended in a constant volume, and total cell counts were determined with a hemacytometer. Differential cell counts were performed on cytocentrifuged preparations stained with DiffQuik (Baxter Healthcare, Miami, FL). BALF supernatants were flash-frozen in liquid nitrogen at the time of collection.
Concentrations of IL-4, IL-5, IL-13, and interferon-␥ (IFN-␥) in BALF were determined using two-site immunoenzymetric assay kits (Endogen, Cambridge, MA) according to the manufacturer's instructions. The lower limits of detection were 1 pg /ml for IL-4, 1 U/ml for IL-5, 40 pg/ml for IFN-␥, and 5 pg/ml for IL-13.
Determination of serum immunoglobulins. Serum samples were obtained by heart puncture. Serum was diluted 40-fold with buffer (PBS ϩ 5% BSA). Total IgE was measured by sandwich ELISA using anti-IgE and biotinylated anti-IgE antibodies (PharMingen, San Diego, CA). RW-specific IgA and IgG1 were determined by applying RW (50 g/ml) in buffer (0.1 M sodium acetate and 1.0 M NaCl, pH 6.5) to 96-well plates overnight, followed by addition of serum samples. Detection of specific immunoglobulin isotypes was performed using biotinylated detection antibodies (PharMingen).
Adoptive transfer of WT and IL-10-KO splenoctyes into SCID mice. Prospective SCID recipient mice were primed with 8 g of RW it 24 h before cell transfer. Splenocytes were isolated from RW-sensitized WT and IL-10-KO donor mice on day 12 of the immunization protocol described above. Mononuclear cells were further enriched by discontinuous density gradient centrifugation (30%/60% Percoll, 2,000 g for 20 min). The SCID recipients received 5 ϫ 10 7 cells ip and 10 7 splenocytes iv. Twenty-four hours following the transfer, SCID recipients were challenged with 8 g of RW it. Control SCID mice were primed and challenged with RW, but no cells were transferred. Evaluation of airway reactivity. Airway reactivity was assayed using three different methodologies. First, enhanced pause (P enh ) was measured in conscious animals using a whole body plethysmograph system (Buxco Electronics, Sharon, CT). At the time of study, the animals were placed in the plethysmograph chamber, and activity was allowed to stabilize for 10 min. Following equilibration, animals were exposed to nebulized saline for 2 min, and P enh was recorded for 5 min to establish a baseline. MCh was dissolved in saline to concentrations of 0.75-48 mg/ml. Animals were exposed to increasing doses of nebulized MCh for 2 min. P enh was monitored continuously for 5 min following each dose of MCh.
Second, airway resistance in anesthetized animals was measured using a Mumed pulmonary function monitoring system (PMS, Mumed, London, UK). Animals were anesthetized with 95 mg/kg ketamine and 5 mg/kg xylazine delivered by intraperitoneal injection. A 20-gauge cannula was inserted into the trachea and connected to a Fleisch 00000 pneumotachograph to monitor air flow. PE-60 tubing was inserted into the esophagus to the level of the thorax to measure transpulmonary pressure. Airway resistance (Raw) was calculated as the quotient of the changes in flow and pressure between isovolumetric points on inspiration and expiration. A 30-gauge cannula was inserted into the tail vein for injection of MCh (Sigma, St. Louis, MO). For doses Ͻ300 g/kg, Raw was recorded for 1 min. For higher doses, Raw was recorded for 2 min after each injection of MCh to allow ample time for breathing to stabilize.
Third, tracheas were excised 72 h after allergen challenge to assess smooth muscle reactivity to MCh. Extraneous tissue was removed, and the tracheas were cut into rings 2 mm wide. Rings were fixed to a strain gauge suspended in KrebsRinger solution containing (in mM) 115 NaCl, 0.4 KH 2 PO 4 , 2.4 K 2 HPO 4 , 25 NaHCO 3 , 1.2 CaCl 2 , and 1.2 MgCl 2 , in 5% CO 2 -95% O 2 . After a 1-h equilibration period, resting tension was set to 1 g. KCl was added to the bathing solution to achieve a final concentration of 50 mM. This was repeated three times, and the maximal tension to 50 mM KCl was recorded. Responses to 10 Ϫ10 to 10 Ϫ4 M MCh were then measured. The protocol was performed twice for each tissue and the values were averaged. Values are reported as a percentage of the maximum tension developed on stimulation of the preparations by KCl.
Statistical analysis. Differences between groups for BALF eosinophils, lymphocytes, IL-4 , IL-5, IL-13, and IFN-␥ content and serum levels of IgA, IgG1, and IgE were determined by ANOVA) A Tukey's honestly significant difference post hoc test was performed to assess significant differences between treatment groups. Differences in dose-response relationships were analyzed using a general linear model for full factorial analysis of repeated measures optimized for polynomial contrast of doses (SPSS, Chicago, IL). F value was corrected for the correlation structure using the GreenhouseGeisser epsilon factor.
RESULTS

Absence of AHR development in RW-sensitized and
-challenged IL-10-KO mice. AHR was first evaluated by measuring changes in Raw to intravenous MCh in anesthetized, spontaneously breathing mice. PBS-challenged WT and IL-10-KO mice exhibited identical dose-response relationships (Fig. 1A) . However, following RW challenge, WT mice exhibited a 2.5-fold increase in Raw to MCh compared with PBS-challenged animals (WT and IL-10-KO) as well as RW-challenged IL-10-KO mice (Fig.  1A , P ϭ 0.001). These observations indicated that IL-10 was involved in development of allergen-induced bronchial hyperresponsiveness to MCh.
Differences in reactivity to MCh were also observed in isolated tracheal ring preparations. In the absence of RW sensitization and challenge (naive groups), minimal reactivity to MCh was detected in either WT or IL-10-KO mice (Fig. 1B) . In addition, hyperresponsiveness to MCh was not observed in either PBS-challenged WT or IL-10-KO mice. However, tracheal rings from RW-challenged WT mice exhibited greater responsiveness to MCh than the naive and PBS-challenged groups (Fig. 1B) . In contrast, responsiveness of rings from RW-sensitized and -challenged IL-10-KO mice was not different from the naive or PBS-challenged groups (Fig. 1B) . These results demonstrated lack of hyperresponsivenss in IL-10 KO mice at the level of the airway smooth muscle.
P enh measurements in conscious unrestrained mice were performed as a noninvasive method of evaluating AHR development (Fig. 1C) . Consistent with Raw, RWchallenged WT mice exhibited AHR, whereas RW-challenged IL-10-KO mice exhibited no AHR to nebulized MCh in the range of 0.75-48 mg/ml (Fig. 1C) . Hamelmann et al. (9) previously demonstrated that P enh is a valid indicator of lower airway function, and since all three of the methods used to evaluate AHR yielded consistent results, further studies of lung function were performed by assessments of P enh alone.
Reconstitution of AHR by rmIL-10 in IL-10-deficient mice. One nanogram of rmIL-10 was administered concomitant with RW challenge to reconstitute IL-10 levels in the airways. In contrast to IL-10-deficient ani- mals, AHR was observed in IL-10-KO animals treated with rmIL10 (Fig. 2) .
Development of AHR in SCID mice following adoptive transfer of WT and IL-10-KO splenocytes.
Airway reactivity was evaluated 72 h after intratracheal challenge in SCID mice adoptively transferred with mononuclear splenocytes from either WT or IL-10-KO mice. SCID mice receiving WT splenocytes exhibited AHR compared with control SCID mice receiving allergen challenge alone. SCID recipients receiving splenocytes from IL-10-KO mice exhibited no AHR (Fig. 3) . These results indicated that the effect of IL-10 on AHR development could be adoptively transferred.
Effect of IL-10 deficiency on Th2 inflammatory parameters. Both RW-sensitized RW-challenged WT and IL-10-KO mice exhibited significant inflammation compared with the corresponding PBS-challenged controls. However, eosinophil and lymphocyte infiltration into the airways 72 h following allergen challenge was greater in IL-10-KO mice than in WT animals ( Table  1) . Administration of 1 ng rmIL-10 at the time of allergen challenge reduced inflammation in IL-10-KO mice by ϳ50% but had minimal effects in WT mice.
Twenty-four hours following RW challenge, both IL-10-KO and WT mice exhibited marked elevations in the levels of IL-4 and IL-5 in the BALF compared with PBS-challenged mice ( Table 2 ). The concentrations of IL-4 and IL-5 in BALF following RW challenge were 40-fold and 3-fold higher, respectively, in IL-10-KO mice compared with similarly treated WT mice. Administration of rmIL-10 (1 ng) in IL-10-KO mice decreased both IL-4 and IL-5 levels in knockout mice, whereas no effect was observed in WT animals. Measurements of IL-13 levels in BALF yielded similar results. Twenty-four hours after RW challenge, BALF from IL-10-KO contained 2,430 Ϯ 649 pg IL-13/ml compared with 239 Ϯ 63 pg/ml in similarly treated WT mice.
Serum levels of IgA, IgG1, and IgE were measured 72 h postchallenge. Relative to WT mice, RW-specific IgA concentrations were twofold greater in serum from RW-sensitized and -challenged IL-10-KO animals (Table 3). Similarly, serum levels of RW-specific IgG1 in RW-challenged IL-10-KO mice were 2.8-fold greater than in similarly treated WT animals (Table 3 ). No differences in IgA and IgG1 were observed in PBSchallenged animals in either genotype. In contrast, total serum IgE levels in IL-10-KO mice challenged with PBS or RW were 5-and 7-fold higher than that in WT mice, respectively (Table 3 ). These data reveal that multiple parameters indicative of Th2 inflammation were elevated in IL-10-KO animals relative to WT animals.
DISCUSSION
This study demonstrates that IL-10-deficient mice fail to express RW-induced AHR to MCh. The lack of AHR was observed in vivo by measuring Raw and in Values are means Ϯ SE; n Ն 6. Twenty-four hours after challenge, mice were anesthetized, the tracheas were cannulated, and lungs were lavaged with two 0.75-ml aliquots of saline. Lung lavages were centrifuged to separate cells from supernatant. Supernatants were assayed for Th2 cytokine concentrations. * Significant difference from PBS-challenged animals of the same strain. † Significant difference from similarly treated WT. ‡ Significant difference from RWchallenged animals of the same strain. P Ͻ 0.05. Fig. 3 . Airway reactivity assessed by whole body plethysmography 72 h after transfer of splenocytes from RW-sensitized IL-10-KO and WT mice to severe combined immunodeficient (SCID) recipient mice. SCID mice were primed with intratracheal RW 24 h before cell transfer and challenged with RW 24 h after cell transfer. Control SCID mice (SCID/it RW) were primed and challenged with RW but received no cell transfusions. Experimental SCID mice received WT mononuclear splenocytes ip and iv (SCID ϩ WT/it RW) or IL-10-KO splenocytes ip and iv (SCID ϩ IL-10-KO/it RW). *Significant difference from SCID/it RW and SCID ϩ IL-10-KO/it RW groups (P Ͻ 0.05, n ϭ 4-5). Values are means Ϯ SE; n Ն 6. Total numbers of cells recovered were analyzed by visual counts with a hemacytometer. Differential counts were obtained by Wright-Giemsa staining of cytospin samples and visual identification and counting. Animals were sensitized with ragweed (RW) and challenged with either PBS (WT/it PBS; IL-10-KO/it PBS), RW (WT/it RW; IL-10-KO/it RW), or RW ϩ 1 ng of recombinant murine interleukin-10 (rmIL-10) (WT/it RW ϩ 1 ng rmIL-10; IL-10-KO/it RW ϩ 1 ng rmIL-10). BALF, bronchoalveolar lavage fluid; WT, wild type; IL, interleukin; IL-10-KO, IL-10-deficient; it, intratracheal. * Significant difference from PBS-challenged animals of the same strain. † Significant difference from similarly treated WT. ‡ Significant difference from RW-challenged animals of the same strain. P Ͻ 0.05.
vitro by measuring tension development in tracheal rings. Interestingly, multiple factors previously implicated as causative agents leading to AHR were upregulated in IL-10-deficient mice, including levels of IL-4, IL-5, IL-13, lymphocytes, and eosinophils in BALF. Reconstitution of IL-10 levels in the airways by administration of rmIL-10 at the time of challenge was sufficient to induce AHR in IL-10-KO mice while concurrently reducing other inflammatory parameters such as IgE levels in the blood, proinflammatory cytokine levels in the airways, and eosinophil infiltration into the BAL compartment. Previously published observations from this laboratory demonstrated that CD4 ϩ Th2 lymphocytes are the predominant IL-10-producing cells in RW-stimulated splenocyte preparations (21) . Taken together, the observations indicate that IL-10 production by RW-specific T cells plays an important role in development of AHR.
Since its initial characterization in 1989 by Fiorentino and colleagues (2), IL-10 has been recognized as a potent anti-inflammatory agent. Using a murine model of allergic airway disease, Zuany-Amorin and colleagues (27) demonstrated that exogenous IL-10 administered concomitant with intratracheal ovalbumin challenge inhibits airway eosinophilia. Grunig and colleagues (7) subsequently demonstrated that Aspergillus fumigatusinduced Th2 inflammation intensifies in the absence of endogenous IL-10, and Tournoy et al. (22) recently demonstrated an enhancement in airway inflammation following ovalbumin challenge in IL-10-deficient mice. Likewise, we observed enhanced Th2 inflammation in the airways of allergen-challenged IL-10-KO mice that was reversed by treatment with rmIL-10. Interestingly, Makela et al. (14) did not observe an effect of IL-10 deficiency on ovalbumin-induced Th2 inflammation within the airways. The reason for the divergence from other studies is not clear at this time.
We observed a reduction in tracheal smooth muscle responsiveness to MCh in allergic IL-10-KO animals. Similarly, Makela et al. (14) reported that tracheal smooth muscle from allergic IL-10-deficient mice was hyporesponsive to electric field stimulation and reconstitution of IL-10 expression via an adenoviral vector reconstituted the smooth muscle hyperresponsiveness. These observations are particularly relevant to the present study in two ways. First, they indicate that IL-10 does not act specifically on the cholinergic pathway. Second, in the present study, allergen-induced eosinophil influx into the airways was elevated in the IL-10-KO mouse, which allowed for the possibility that high levels of inflammation may have inhibited smooth muscle function. The fact that Makela et al. (14) observed attenuated smooth muscle responses in IL-10-KO mice in the absence of elevated Th2 inflammation argues against such a mechanism.
The inflammatory parameters measured in this study (i.e., BALF levels of IL-4, IL-5, IL-13, eosinophils, lymphocytes and serum levels of IgG1, IgA, and IgE) have been associated with AHR development. Specifically, Garlisi et al. (5) (17) . Due to the significant elevation in all of these factors in IL-10-deficient mice, the data presented in this study suggest that, while these factors may be associated with AHR development, alone they cannot precipitate AHR development. Although the activation state of eosinophils was not addressed in these studies (as well as in this report), an earlier study demonstrated that the levels of eosinophil peroxidase and leukotriene C 4 were significantly elevated within the airways of IL-10-deficient mice compared with those in WT control mice (14) . Therefore, the absence of AHR development in IL-10-deficient mice also does not appear to be due to the lack of activated eosinophils within the airways of these mice.
The mechanism by which IL-10 facilitates development of AHR is not known, but the evidence indicates that it acts in concert with one or more inflammatory factors to increase smooth muscle reactivity. The following observations support this theory. First, allergic sensitization and challenge are required to observe the effect of IL-10. In WT animals, IL-10 alone has no effect on airway responses to MCh (24) . Second, reactivity to MCh is similar in naive WT and IL-10-deficient mice, indicating that IL-10 does not directly stimulate airway constriction. Third, a strong correlation exists between Th2 inflammation and AHR in IL-10-sufficient animals, but that correlation breaks down in the absence of IL-10. Fourth, a similar degree of hyperresponsiveness is observed in WT mice regardless of whether the readout is Raw, P enh , or tracheal ring contraction. AHR in this model is therefore a reflection of smooth muscle activation. Fifth, as discussed above, IL-10 production by Th2 cells is critical to AHR development in this model, which indicates the need for Values are means Ϯ SE; n Ն 6. Mice were anesthetized and blood samples were taken by heart puncture. A 550 , absorbance at 550 nm. * Significant difference from PBS-challenged animals of the same strain. † Significant difference from similarly treated WT. P Ͻ 0.05.
other coincident lymphocyte-derived signals in the process. Thus AHR in this model involves the induction of smooth muscle hyperresponsiveness.
Shibata and colleagues (21) previously demonstrated that splenocytes from RW-sensitized WT C57BL/6 mice produce IL-4, IL-5, and IL-10 but not IFN-␥ when stimulated with RW in vitro. Depletion of the CD4 ϩ cells by complement-dependent cell lysis reduces IL-4 and IL-5 production by Ͼ80% and IL-10 production by 94%, indicating that RW-specific Th2 cells are the major source of IL-10 in isolated splenocytes. These observations, in combination with the results of the adoptive transfer experiments in the present study, indicate that IL-10 production by Th2 lymphocytes is required for development of AHR in this model. In summary, current evidence indicates that IL-10 downregulates allergen-induced Th2 inflammation within murine airways, yet is critical for the development of AHR in this model. While the mechanism is unclear, it is likely that IL-10 functions in concert with one or more inflammatory factors to precipitate AHR via an indirect effect on airway smooth muscle.
